Please login to the form below

Not currently logged in
Email:
Password:

Amicus forms gene therapy manufacturing partnership with Catalent

Biotech invests to speed gene therapies into clinical trials

amicus

US biotech Amicus Therapeutics is to work with drug development services company Catalent Biologics to develop its cell and gene therapy manufacturing capabilities.

It has been investing heavily in the field this year, including its $100m acquisition of Celenex last September, bringing with it no fewer than 10 pipeline gene therapy programmes.

Amicus will work with Paragon Gene Therapy, which Catalent acquired earlier this year in a $1.2bn deal to boost its own presence in the fast-developing field.

Amicus has one rare disease medicine already on the market, Galafold for Fabry disease, with an enzyme replacement therapy (AT-GAA) for Pompe disease in its late stage pipeline, to which it has added the gene therapy pipeline and lysosomal storage disorders treatments in early development.

The newly dubbed Paragon Gene Therapy unit is set up to help  development of gene therapies, vaccines, and oncology immunotherapies, and facilitate quick market access.

John Crowley

John Crowley

John F. Crowley, chairman and CEO of Amicus, said: “Leveraging our internal expertise and process development in combination with Paragon’s expertise and platform capabilities, we hope to expedite the process of moving our preclinical gene therapy programmes into the clinic as quickly as possible.”

The agreement will also see the development of an Adeno-Associated Virus (AAV) manufacturing platform, supporting the manufacturing of Amicus’ preclinical gene therapy programmes.

The partners will also work on a Pompe pre-clinical gene therapy programme, which will see an initial technology transfer and process development to focus on the Amicus AAV gene therapy programme.

Pete Buzy, president of Paragon Gene Therapy, said: “Paragon has a proven track record to develop and successfully manufacture complex biotherapeutics using commercially-scalable processes. This agreement with Amicus highlights our world-class manufacturing team and our track record as a center of excellence for gene therapy, trusted by top biopharmaceutical companies.”

The alliance announced yesterday adds to a similar strategic manufacturing collaboration with Thermo Fisher Scientific, the contract development and manufacturing organisation (CDMO) which also has late-stage clinical and commercial-scale capabilities.

Thermo Fisher will supply Amicus with immediate access to clinical and commercial manufacturing capabilities and capacity for its intrathecal AAV Batten disease gene therapy programmes.

Article by
Lucy Parsons

3rd July 2019

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

Data desires
What are you looking to achieve with data and how are you preparing yourself to react to the results?...
The balancing act that’s keeping pharma and biotech market access on its toes
Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to...
Pills
Tackling antimicrobial resistance on multiple fronts
An urgent change of direction is needed in how we respond to AMR...

Infographics